ArticleFrontiers in oncology2026
Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer, characterized by its high global incidence and mortality rates, necessitates comprehensive and precise stratification strategies to guide the diverse diagnostic approaches and therapeutic agents in clinical decision-making. Objectives: Shox2 and Rassf1a promoter methylation are established biomarkers for the early screening of lung cancer. This study comprehensively investigated the clinical utility of Shox2 and Rassf1a promoter methylation alongside driver mutations for molecular subtyping and stratification in 1027 lung adenocarcinoma (LUAD) patients. Methods: This study included a cohort of 1027 LUAD patients who received treatment at the First Affiliated Hospital of Chongqing Medical University between January 2020 and August 2024. Comprehensive demographic and clinicopathological data were collected. Shox2 and Rassf1a methylation was quantified using the Lungme kit, while 10 driver mutations were detected by PCR assay. Chi-square tests were used to assess correlations between methylation status and clinicopathological characteristics; ROC analysis evaluated diagnostic performance for distinguishing LUAD subtypes. Multiple regression identified stage-associated hazardous factors. Results: In our cohort, Shox2 and Rassf1a methylation were correlated with more aggressive clinicopathological characteristics (age, sex, smoking, drinking, TNM stage and histological progression) and exhibited significant diagnostic potential for distinguishing early-stage lesions (adenocarcinoma Conclusions: Our study demonstrated that comprehensive analysis of methylation and gene mutations could provide a novel clinical strategy for molecular subtyping and precision medicine in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.